hackint0sh/New-Dataset huggingface dataset:
This study will be done by using a very small sample of uterine tissue, taken from the incision site, following delivery by cesarean section. The sample is taken to the laboratory and will be exposed to carbetocin followed by other uterotonic drugs. The information obtained from this study will help modify the treatment for uterine atony and post-delivery bleeding to lower the risk further. conditions: Postpartum Hemorrhage studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 32 type: ESTIMATED name: Carbetocin name: Oxytocin name: Carbetocin name: Oxytocin name: Ergonovine name: Carboprost measure: Motility index measure: Amplitude of contraction measure: Frequency of contraction measure: Integrated area under response curve (AUC) sex: FEMALE minimumAge: 18 Years maximumAge: 45 Years stdAges: ADULT facility: Mount Sinai Hospital status: RECRUITING city: Toronto state: Ontario zip: M5G1X5 country: Canada name: Mrinalini Balki, MD role: CONTACT phone: 416-586-4800 phoneExt: 5270 email: mrinalini.balki@uhn.ca name: Wafa Bellan, MD role: SUB_INVESTIGATOR name: Ronald George, MD role: SUB_INVESTIGATOR name: Joseph Park, BSc role: SUB_INVESTIGATOR name: Anuradha Baishnob, BSc role: SUB_INVESTIGATOR lat: 43.70011 lon: -79.4163 hasResults: False
nctId: NCT06285396 id: 24-01 briefTitle: Effect of Ephedrine, Phenylepinephrine, and Norepinephrine on Myometrial Contractility in Pregnant People With Type II and Gestational Diabetes During Cesarean Section: An In-vitro Study overallStatus: RECRUITING date: 2024-03-18 date: 2024-07 date: 2024-07 date: 2024-02-29 date: 2024-04-12 name: Samuel Lunenfeld Research Institute, Mount Sinai Hospital class: OTHER briefSummary: The goal of this study is to learn about how medication that is used to help treat low blood pressure during a Cesarean delivery (CD) can cause changes to the uterine muscle tissue and its ability to contract, in patients with Type II and gestational diabetes.
Spinal anesthesia administered during elective CD has been known to cause hypotension (low blood pressure) as a side effect during the procedure, and is prevented by administration of vasopressors (medication to raise blood pressure) by the anesthesiologist after the delivery of the baby. Vasopressors treat hypotension by interacting with receptors on blood vessels that increase blood pressure, which can also cause changes to uterine contractility. Inadequate uterine contraction after CD can expose mothers to postpartum hemorrhage (PPH), with diabetic patients displaying a 2.5-times higher risk of PPH.
It is important to understand how vasopressor(s) might affect the uterine contractility of women with Type II and gestational diabetes. Since medication to contract the uterus is also routinely administered at delivery, it is important to study the effect of these drugs in combination. The purpose of this study is to compare uterine contractility patterns and receptor distribution in women with type II and gestational diabetic and control term pregnant patients with administration of vasopressors. This will be done using small uterine tissue samples taken from the incision site following CD, which will then be used for experiments in the laboratory. conditions: Postpartum Hemorrhage studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 24 type: ESTIMATED name: Ephedrine name: Phenylephrine name: Norepinephrine name: Oxytocin measure: Motility index measure: Amplitude of contraction measure: Frequency of contraction measure: Integrated area under response curve (AUC) sex: FEMALE minimumAge: 19 Years maximumAge: 40 Years stdAges: ADULT facility: Mount Sinai Hospital status: RECRUITING city: Toronto state: Ontario zip: M5G1X5 country: Canada name: Mrinalini Balki, MD role: CONTACT phone: 416-586-4800 phoneExt: 5270 email: mrinalini.balki@uhn.ca name: Caroline Carruthers role: SUB_INVESTIGATOR name: Joseph Park, BSc role: SUB_INVESTIGATOR name: Cynthia Maxwell, MD role: SUB_INVESTIGATOR name: Anuradha Baishnob, BSc role: SUB_INVESTIGATOR lat: 43.70011 lon: -79.4163 hasResults: False
nctId: NCT06285383 id: Kar.neck briefTitle: The Effects of Music on Neck Pain overallStatus: RECRUITING date: 2024-02-15 date: 2024-03-15 date: 2024-04-15 date: 2024-02-29 date: 2024-02-29 name: KTO Karatay University class: OTHER briefSummary: The effects of passive music listening on pain, anxiety and quality of life in patients with chronic neck pain in addition to physical therapy will be examined. conditions: Pain, Chronic studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: SINGLE whoMasked: PARTICIPANT count: 60 type: ESTIMATED name: Music listening name: classic physical therapy measure: Beck anxiety inventory measure: Visual Analogue Scale measure: Short form-36 sex: ALL minimumAge: 30 Years maximumAge: 50 Years stdAges: ADULT facility: Mustafa Savaş Torlak status: RECRUITING city: Karatay state: Eyalet/Yerleşke zip: 42000 country: Turkey name: Mustafa S Torlak role: CONTACT phone: +905373660138 email: mustafa.savas.torlak@karatay.edu.tr lat: 37.86726 lon: 32.52863 hasResults: False
nctId: NCT06285357 id: EPISTOP_22 briefTitle: The Effect of the Association EGCG, Folic Acid and Vitamin B12 in Preventing the Persistence of HPV Infection. overallStatus: RECRUITING date: 2024-02-19 date: 2025-02 date: 2025-12 date: 2024-02-29 date: 2024-03-18 name: Lo.Li.Pharma s.r.l class: INDUSTRY briefSummary: The purpose of the study is to test the effect of the administration of a dietary supplement consisting of epigallocatechin gallate (EGCG), vitamin B12 and folic acid in the treatment of infections with papilloma virus of the cervix. conditions: HPV Infection studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 100 type: ESTIMATED name: EGCG + folic acid + B12 measure: HPV DNA test negativity sex: FEMALE minimumAge: 25 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Azienda Ospedaliero-Universitaria di Modena status: RECRUITING city: Modena zip: 41124 country: Italy name: Giovanni Grandi role: CONTACT lat: 44.64783 lon: 10.92539 hasResults: False
nctId: NCT06285344 id: kilis_3 briefTitle: Impact of Workload and Fatigue on Sleep in OR Nurses overallStatus: NOT_YET_RECRUITING date: 2024-04-01 date: 2024-05-01 date: 2024-06-01 date: 2024-02-29 date: 2024-02-29 name: Kilis 7 Aralik University class: OTHER name: Hasan Kalyoncu University briefSummary: This study aims to explore the impact of individual workload and fatigue levels on the sleep quality of operating room (OR) nurses, highlighting a critical aspect of healthcare professionals' well-being that directly affects patient safety and care quality. Operating room nurses face unique challenges due to the high-stress, fast-paced environment of surgical settings, which can lead to increased stress levels, emotional challenges, and a higher incidence of fatigue compared to other nursing specialties. Factors contributing to this fatigue include the demanding nature of surgical procedures, the need for constant vigilance, and the irregular hours associated with shift work, all of which can impair sleep quality.
The literature review suggests that while the relationship between workload, fatigue, and sleep quality has been extensively studied in general nursing populations, there is a lack of specific focus on operating room nurses. These professionals work under distinct conditions that may exacerbate the effects of workload and fatigue on sleep quality, yet comprehensive studies targeting this group are limited. Understanding the nuances of how workload and fatigue specifically impact the sleep quality of OR nurses is crucial for developing targeted interventions aimed at improving their health and job performance, thereby enhancing patient care and safety.
This cross-sectional and correlational study seeks to fill the gap in the literature by examining the specific effects of workload and fatigue on sleep perception among OR nurses. By identifying these relationships, the study aims to contribute valuable insights into strategies for mitigating fatigue and improving sleep among this critical group of healthcare workers, with the ultimate goal of ensuring both nurse well-being and patient safety. conditions: Shift Work conditions: Sleep Perception studyType: OBSERVATIONAL observationalModel: OTHER timePerspective: CROSS_SECTIONAL count: 250 type: ESTIMATED measure: Demographic Information Form measure: Individual Workload Perception Scale (IWPS) measure: Chalder Fatigue Scale (CFS) measure: Richard-Campbell Sleep Questionnaire (RCSQ) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Islam Elagöz city: Kilis zip: 79100 country: Turkey lat: 36.71611 lon: 37.115 hasResults: False
nctId: NCT06285331 id: 2023ZDSYLL483-P01 briefTitle: the Impact of Manual or Mechanical Ways to Perform PLR on the Accuracy of Evaluation of Fluid Responsiveness acronym: PLR overallStatus: RECRUITING date: 2023-11-06 date: 2025-12-31 date: 2025-12-31 date: 2024-02-29 date: 2024-03-04 name: Southeast University, China class: OTHER briefSummary: Our goal was to study the impact of different ways to perform passive leg raising (PLR) on the accuracy of evaluation of fluid responsiveness. conditions: Circulatory Failure studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: SUPPORTIVE_CARE masking: SINGLE whoMasked: PARTICIPANT count: 60 type: ESTIMATED name: Automatic Bed name: Manual measure: Accuracy of fluid responsiveness evaluation measure: Mortality sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Zhongda Hospital Southeast University status: RECRUITING city: Nanjing state: Jiangsu zip: 210009 country: China name: Jingyuan Xu, M.D. role: CONTACT lat: 32.06167 lon: 118.77778 hasResults: False
nctId: NCT06285305 id: kilis_2 briefTitle: Surgical ICU Nurses' Attitudes on End-of-Life Care overallStatus: NOT_YET_RECRUITING date: 2024-04-01 date: 2024-05-01 date: 2024-06-01 date: 2024-02-29 date: 2024-02-29 name: Kilis 7 Aralik University class: OTHER name: Hasan Kalyoncu University briefSummary: This study aims to explore the attitudes and behaviors of nurses working in surgical intensive care units (ICUs) towards end-of-life care, alongside identifying the barriers they face in providing such care. Despite the universal need for end-of-life care, with an estimated 56.8 million people requiring it annually, only a fraction receive adequate services. The concept of a "good death" has evolved, now emphasizing patient and family wishes, and aligning with clinical, cultural, and ethical standards. In the U.S., a significant portion of deaths occur in hospitals, often involving surgical interventions in the final stages of life. Nurses in ICUs play a crucial role in delivering end-of-life care, making their attitudes and behaviors pivotal to the quality of care provided. Previous studies have indicated a positive correlation between nurses' attitudes towards end-of-life care and their ethical conduct in care delivery. However, research specifically focusing on surgical ICU nurses and the challenges they encounter in end-of-life care is limited. This study seeks to fill that gap, enhancing understanding of the factors that influence end-of-life care in surgical ICUs and potentially guiding improvements in care practices and policy. conditions: PATİENT CARE conditions: Intensive Care Unit studyType: OBSERVATIONAL observationalModel: CASE_CROSSOVER timePerspective: PROSPECTIVE count: 250 type: ESTIMATED measure: Descriptive Information Form measure: Attitudes and Behaviors Towards End-of-Life Care Scale for Intensive Care Nurses measure: Barriers to End-of-Life Care in Surgical Intensive Care Form sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Islam city: Kilis zip: 79100 country: Turkey lat: 36.71611 lon: 37.115 hasResults: False
nctId: NCT06285292 id: RC24_0097 briefTitle: Prospective and Comparative Evaluation of a Medical Device Composed of a Perineal Probe Connected to a Mobile Application in the Management of Stress Urinary Incontinence. acronym: PRIME overallStatus: NOT_YET_RECRUITING date: 2024-06 date: 2024-06 date: 2026-06 date: 2024-02-29 date: 2024-02-29 name: Nantes University Hospital class: OTHER name: FIZIMED Company briefSummary: Stress urinary incontinence (SUI) affects around 40% of women and has a major impact on quality of life. The gold standard for the treatment of SUI is pelvicfloor rehabilitation, but this presents constraints in terms of availability of healthcare professionals, as well as organization and travel for patients. Innovative devices offer self-training exercises for the pelvicfloor, thus promoting motivation and adherence to treatment. The hypothesis of this study is to prove that the use of a pelvicfloor medical device combined with 2 rehabilitation sessions is not inferior to pelvic-perineal rehabilitation. conditions: Urinary Incontinence studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 138 type: ESTIMATED name: EMY measure: Urinary symptoms using the ICIQ-UI SF questionnaire measure: Quality of life using the I-QoL questionnaire measure: Urinary symptoms using the ICIQ-UI SF questionnaire measure: Cost-utility ratio using the EQ-5D questionnaire measure: Qualitative component sex: FEMALE minimumAge: 18 Years maximumAge: 60 Years stdAges: ADULT hasResults: False
nctId: NCT06285279 id: NJCT-2401 briefTitle: FKC288 in Participants With Autoimmune Kidney Diseases overallStatus: RECRUITING date: 2024-03-04 date: 2026-12-31 date: 2028-12-31 date: 2024-02-29 date: 2024-04-02 name: Nanjing University School of Medicine class: OTHER briefSummary: This study is a single-center, open-label, dose-escalation exploratory clinical trial, expected to enroll 6 to 12 participants. It will use a BOIN (Bayesian Optimal Interval) design for dose escalation, with four predetermined dose groups (0.3×10\^6 cells/kg, 1.0×10\^6 cells/kg, 3.0×10\^6 cells/kg, and an alternative dose of 0.1×10\^6 cells/kg). Each dose group plans to enroll 1-2 or 3-6 participants with relapsed or refractory autoimmune-mediated kidney diseases (such as lupus nephritis, ANCA-associated vasculitis, membranous nephropathy, and IgG4-related diseases). conditions: Lupus Nephritis conditions: ANCA-associated Vasculitis conditions: Membranous Nephropathy - PLA2R Induced conditions: IgG4-Related Diseases studyType: INTERVENTIONAL phases: PHASE1 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 24 type: ESTIMATED name: FKC288 measure: The proportion of subjects with dose-limiting toxicity measure: The proportion of subjects with adverse events measure: Proportion of subjects achieving renal response measure: Duration of response (DoR) of all subjects measure: Progression-free survival (PFS) of all subjects measure: Overall survival (OS) of all subjects sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Jinling Hospital status: RECRUITING city: Nanjing state: Jiangsu zip: 210016 country: China name: Xianghua Huang, MD role: CONTACT phone: 13770648824 email: hxhszb@163.com lat: 32.06167 lon: 118.77778 hasResults: False
nctId: NCT06285266 id: kilis_1 briefTitle: Nursing Students' Perceptions and Participation in Surgical Clinical Learning acronym: NSPSCP_CL overallStatus: NOT_YET_RECRUITING date: 2024-03-15 date: 2024-04-30 date: 2024-06-01 date: 2024-02-29 date: 2024-02-29 name: Kilis 7 Aralik University class: OTHER name: Hasan Kalyoncu University briefSummary: This cross-sectional study investigates the perceptions of nursing students regarding the clinical learning environment (CLE) in surgical services and their participation in clinical practices. Surgical services present a complex, dynamic, and intense learning environment crucial for the development of nursing students' professional competencies. The study explores the challenges nursing students face in these settings, including limited opportunities for participation in intraoperative processes and intensive care units, and the impact of these challenges on their learning outcomes and professional development.
Keywords: Nursing Student, Surgical Services, Clinical Practice, Clinical Learning Environment conditions: Clinical Practice studyType: OBSERVATIONAL observationalModel: OTHER timePerspective: CROSS_SECTIONAL count: 100 type: ESTIMATED measure: Descriptive Characteristics Form measure: Clinical Learning Environment Scale (CLES): measure: Clinical Practice Participation Determination Form: sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06285253 id: MIRO-01-001 briefTitle: miroliverELAP® for the Treatment of Acute Liver Failure: A Phase 1 Trial overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2025-01-31 date: 2025-02-28 date: 2024-02-29 date: 2024-03-29 name: Miromatrix Medical Inc. class: INDUSTRY briefSummary: The clinical trail will assess the safety of miroliverELAP for the treatment of acute liver failure without underlying chronic liver disease. miroliverELAP is an external liver assist combination product consisting of a single-use MIRO-001 bioengineered liver graft and an extracorporeal blood circuit. miroliverELAP Is intended to support the native (failed) liver for up to 48-hours of continuous treatment to allow time for liver recovery or to identify a transplantable liver. conditions: Acute Liver Failure conditions: Acute Liver Injury, Drug Induced studyType: INTERVENTIONAL phases: PHASE1 allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: Single arm, open label, safety study primaryPurpose: TREATMENT masking: NONE count: 15 type: ESTIMATED name: miroliverELAP treatment measure: Survival measure: Adverse Events measure: 21-day survival sex: ALL minimumAge: 18 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University of California San Francisco Medical Center city: San Francisco state: California zip: 94143 country: United States name: Bilal Hameed, MD role: CONTACT lat: 37.77493 lon: -122.41942 facility: Emory University School of Medicine city: Atlanta state: Georgia zip: 30322 country: United States lat: 33.749 lon: -84.38798 facility: Northwestern Memorial Hospital city: Chicago state: Illinois zip: 60611 country: United States name: Justin Boike, MD role: CONTACT lat: 41.85003 lon: -87.65005 facility: University of Michigan Medical School city: Ann Arbor state: Michigan zip: 48109 country: United States name: Lena Napolitano, MD role: CONTACT lat: 42.27756 lon: -83.74088 facility: University of Minnesota Medical School city: Minneapolis state: Minnesota zip: 55455 country: United States name: Thomas Leventhal, MD role: CONTACT lat: 44.97997 lon: -93.26384 facility: Mayo Clinic city: Rochester state: Minnesota zip: 55902 country: United States lat: 44.02163 lon: -92.4699 facility: Mount Sinai Recanati/Miller Transplantation Institute city: New York state: New York zip: 10029 country: United States lat: 40.71427 lon: -74.00597 facility: Cleveland Clinic Foundation city: Cleveland state: Ohio zip: 44195 country: United States lat: 41.4995 lon: -81.69541 facility: Intermountain Healthcare city: Salt Lake City state: Utah zip: 84103 country: United States name: Richard Gilroy, MD role: CONTACT lat: 40.76078 lon: -111.89105 facility: Virginia Commonwealth University Medical Center city: Richmond state: Virginia zip: 23970 country: United States lat: 37.55376 lon: -77.46026 hasResults: False
nctId: NCT06285240 id: 1167-007 briefTitle: Efficacy and Safety of MK-1167 in Participants With Alzheimer's Disease Dementia Taking Stable Donepezil Treatment (MK-1167-007) overallStatus: RECRUITING date: 2024-03-28 date: 2024-07-25 date: 2024-07-25 date: 2024-02-29 date: 2024-04-03 name: Merck Sharp & Dohme LLC class: INDUSTRY briefSummary: The main purpose of this study is to assess the safety and efficacy of MK-1167 administered to participants with Alzheimer's Disease (AD) receiving stable Donepezil treatment. conditions: Alzheimer's Disease studyType: INTERVENTIONAL phases: PHASE1 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 16 type: ESTIMATED name: MK-1167 name: Donepezil name: Placebo measure: Number of participants experiencing an Adverse Event (AE) measure: Number of participants discontinuing study treatment due to an AE measure: Area Under the Plasma Concentration-Time Curve from Dosing to 24 Hours Postdose (AUC0-24) of MK-1167 measure: Maximum Plasma Concentration (Cmax) of MK-1167 measure: Plasma Concentration at 24 hours postdose (C24) measure: Time to Reach Maximum Plasma Concentration (Tmax) of MK-1167 measure: Apparent Terminal Half-Life (t½) of MK-1167 measure: Oral Clearance (CL/F) of MK-1167 from Plasma measure: Apparent Volume of Distribution (Vz/F) of MK-1167 sex: ALL minimumAge: 50 Years maximumAge: 90 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Velocity Clinical Research, Hallandale Beach ( Site 0001) status: RECRUITING city: Hallandale Beach state: Florida zip: 33009 country: United States name: Study Coordinator role: CONTACT phone: 954-455-5757 lat: 25.9812 lon: -80.14838 facility: CenExel iResearch, LLC ( Site 0003) status: RECRUITING city: Decatur state: Georgia zip: 30030 country: United States name: Study Coordinator role: CONTACT phone: 404-537-1281 lat: 33.77483 lon: -84.29631 facility: CenExel iResearch, LLC ( Site 0004) status: RECRUITING city: Savannah state: Georgia zip: 31405 country: United States name: Study Coordinator role: CONTACT phone: 912-744-0800 lat: 32.08354 lon: -81.09983 hasResults: False
nctId: NCT06285227 id: CM313-100001 briefTitle: Study of CM313 in Healthy Subjects overallStatus: NOT_YET_RECRUITING date: 2024-04-30 date: 2025-04-30 date: 2025-04-30 date: 2024-02-29 date: 2024-02-29 name: Keymed Biosciences Co.Ltd class: INDUSTRY briefSummary: This study is a single center, randomized, open/double-blind, placebo-controlled, single dose, dose escalation Phase I clinical study aimed at evaluating the safety, tolerability, pharmacokinetics, pharmacokinetic characteristics, and immunogenicity of CM313 administered subcutaneously or intravenously at different doses in healthy male subjects. conditions: Healthy studyType: INTERVENTIONAL phases: PHASE1 allocation: RANDOMIZED interventionModel: SEQUENTIAL primaryPurpose: TREATMENT masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 51 type: ESTIMATED name: CM313 injection measure: Adverse event sex: MALE minimumAge: 18 Years maximumAge: 50 Years stdAges: ADULT hasResults: False